Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$84 Mln
P/E Ratio
--
P/B Ratio
10.06
Industry P/E
--
Debt to Equity
0.03
ROE
-1.03 %
ROCE
-99.76 %
Div. Yield
0 %
Book Value
0.21
EPS
-0.25
CFO
$-69.17 Mln
EBITDA
$-87.38 Mln
Net Profit
$-81.99 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Entera Bio - ADR (ENTX)
| -0.94 | 7.69 | -15.66 | 2.44 | -7.92 | 2.46 | -- |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|
|
Entera Bio - ADR (ENTX)
| -17.81 | -74.07 | 160.65 | -49.53 | -29.84 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 2.24 | 26.92 | -- | -79.46 | |
| 1.44 | 135.92 | -- | -23.63 | |
| 0.90 | 20.81 | -- | -70.86 | |
| 10.25 | 445.73 | -- | 342.83 |
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The company leverage its N-Tab, an... oral delivery technology, which is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. Its advanced product candidate is EB613 (oral PTH (1-34)) that is entering into Phase 3 development as the first oral, osteoanabolic (bone-building) once-daily tablet treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis. The company is also developing EB612 as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. In addition, it is developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and the first oral GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. Address: Kiryat Hadassah Minrav Building, Jerusalem, Israel, 9112002 Read more
CEO & Director
Ms. Miranda J. Toledano M.B.A.
CEO & Director
Ms. Miranda J. Toledano M.B.A.
Headquarters
Jerusalem
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Entera Bio Ltd - ADR (ENTX) stood at $ 9 Mln as on 31-Dec-24
The share price of Entera Bio Ltd - ADR (ENTX) is $2.10 (NASDAQ) as of 23-Apr-2025 14:23 EDT. Entera Bio Ltd - ADR (ENTX) has given a return of -7.92% in the last 3 years.
Entera Bio Ltd - ADR (ENTX) has a market capitalisation of $ 84 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Entera Bio Ltd - ADR (ENTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Entera Bio Ltd - ADR (ENTX) and enter the required number of quantities and click on buy to purchase the shares of Entera Bio Ltd - ADR (ENTX).
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The company leverage its N-Tab, an oral delivery technology, which is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. Its advanced product candidate is EB613 (oral PTH (1-34)) that is entering into Phase 3 development as the first oral, osteoanabolic (bone-building) once-daily tablet treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis. The company is also developing EB612 as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. In addition, it is developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and the first oral GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. Address: Kiryat Hadassah Minrav Building, Jerusalem, Israel, 9112002
The CEO & director of Ms. Miranda J. Toledano M.B.A.. is Entera Bio Ltd - ADR (ENTX), and CFO & Sr. VP is Ms. Miranda J. Toledano M.B.A..
There is no promoter pledging in Entera Bio Ltd - ADR (ENTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
48
|
|
|
15
|
|
|
5
|
|
|
3
|
| Entera Bio Ltd. - ADR (ENTX) | Ratios |
|---|---|
|
Return on equity(%)
|
-103.34
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-5271.27
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Entera Bio Ltd - ADR (ENTX) was $0 Mln.
$0.14
(
